The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single arm prospective study evaluating the relationship of ctDNA molecular complete response (mCR) and pathologic complete response (pCR) in a diverse early triple-negative breast cancer patient (TNBC) population receiving neoadjuvant chemotherapy (NAC).
 
Elizabeth John
No Relationships to Disclose
 
Simranjit Sekhon
No Relationships to Disclose
 
Terrence Jones
No Relationships to Disclose
 
Parnian Kheirkhah Rahimabad
No Relationships to Disclose
 
Christine Son
No Relationships to Disclose
 
Srishti Sareen
No Relationships to Disclose
 
Laila Vidal
No Relationships to Disclose
 
Sonia Benn
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca
 
Leonard Harris
No Relationships to Disclose
 
Gregory Vidal
Employment - Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
Consulting or Advisory Role - AstraZeneca; AstraZeneca/Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Lilly; Merck; Myriad Genetics; Novartis; Pfizer; Seagen; Stemline Therapeutics
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Celcuity; Daiichi Sankyo; EMD Serono; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Lilly; Myriad Genetics; Natera; Puma Biotechnology; Tesaro
Travel, Accommodations, Expenses - AstraZeneca